로딩 중…
StockDiggingStockDigging

DongKook Life Science

303810· KOSDAQ
₩2,735-4.70%
2026-06-19

Price Chart

DongKook Life Science-40.54%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap87.48B KRW
Revenue128.38B KRW
Net Income1.20B KRW
Total Assets223.83B KRW
Net Assets133.64B KRW
Employees211
Value
P/E72.78x
P/B0.65x
PEG29.17x
P/S0.68x
EV/EBITDA43.69x
FCF Yield-6.01%
Profitability
ROE0.90%
ROA0.54%
Op. Margin2.17%
Revenue Growth-5.61%
Earnings Growth2.50%
Financial Health
Debt Ratio167.49%
Total Debt39.27B KRW
FCF-5.26B KRW
Cash4.88B KRW
Current Ratio1.71x
Net Debt/EBITDA12.33x
Performance
1Y Return-40.54%
1M Return-8.22%
From 52W High-48.88%
1Y MDD-48.16%
Trading
Volume63,181 shares
Foreign Own.2.45%
Per Share
EPS272 KRW
BPS4,178 KRW

Company Info

CEO 박재원
Employees 211
Founded 2017
HQ 서울특별시 강남구, KR
Website dkls.co.kr

Dongguk Pharmaceutical Life Science, established in 2017 and listed on KOSDAQ in 2025, manufactures and sells contrast agents, and distributes medical devices and diagnostic equipment. As a specialized contrast agent company, it launched Korea's first First generic contrast agent, Pamiray, and has 17 partners in 25 countries. Leveraging its radiology expertise and sales network from its contrast agent business, the company is expanding its AI medical device business and providing Total Patient Care. It is headquartered in Gangnam-gu, Seoul.